| Date | Title | Description |
| 10.03.2025 | Cambridge Innovation Capital: £100 Million Opportunity Fund Closed | Cambridge Innovation Capital (CIC), a leading venture capital firm embedded in the Cambridge ecosystem, announced it has launched a new £100 million Opportunity Fund – which is anchored by Aviva Investors and British Patient Capital – to in... |
| 24.02.2025 | Cambridge Innovation Capital launches £100m Opportunity Fund | Aviva Investors and British Patient Capital lead investment into new growth fund addressing the UK’s scale-up funding gap.
24 February 2025, Cambridge, UK — Cambridge Innovation Capital (CIC), the leading venture capital firm embedded in th... |
| 24.02.2025 | Cambridge Innovation Capital launches £100M Fund for deeptech and life sciences | Cambridge Innovation Capital (CIC) has today launched a new £100 million Opportunity Fund to invest in growth stage deep tech and life sciences companies.
With up to £20 million per investment into later-stage rounds of deep tech and life s... |
| 23.02.2025 | 18th Annual European Life Sciences CEO Forum | The 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF is spread over 2 days (26th - 27th of Februar... |
| 11.02.2025 | Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors | - Tosh, formerly President of Idorsia and Chief Operating Officer of ChemoCentryx, brings more than 20 years of leadership experience from global pharma and biotech companies
- Khurem Farooq, Chief Executive Officer of Verdiva Bio and forme... |
| 12.01.2025 | European Tech Landscape: A Surge of Innovation and Investment | The European tech scene is buzzing. A recent wave of funding, acquisitions, and innovative breakthroughs paints a vibrant picture of the continent's entrepreneurial spirit. This week alone, over 40 tech funding deals topped €1.3 billion. Th... |
| 10.01.2025 | Verdiva Bio launches with $411M Series A raise for next-gen oral and injectable treatments for obesity | Pharmatech company Verdiva Bio launched this week with an eye-watering $411 million Series A.
Focused on developing innovative therapies for obesity and other cardiometabolic disorders, Verdiva Bio is creating next-generation oral and injec... |
| 09.01.2025 | Forbion Co-Leads over $410M Series A Financing to Launch Verdiva Bio, a Clinical-Stage Cardiometabolic Company Advancing Next-Generation Therapies | - Co-founded by Khurem Farooq and former members of Aiolos Bio team to develop broad portfolio of oral and injectable treatments for obesity, cardiometabolic disorders, and related complications
- Forbion played an instrumental role in the ... |
| 16.05.2024 | enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder c... |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent board member |
| 11.01.2023 | Novartis' CEO said gene therapy is a 'nuanced puzzle' everyone is trying to figure out, but he's still committed to the cutting-edge treatments | Vas Narasimhan, the CEO of Novartis. Reuters This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Novartis' gene-therapy efforts haven't moved as fast as expected, CEO Vas Narasimhan said.
Whi... |
| 09.11.2021 | Gyroscope Therapeutics Receives Up To $60M Equity Investment From Sanofi | Gyroscope Therapeutics Holdings plc, a London, UK-based clinical-stage gene therapy company focused on diseases of the eye, received an up to $60m equity investment from global biopharmaceutical company Sanofi.
Sanofi will invest $40.0m in ... |
| 08.11.2021 | Gyroscope Therapeutics Announces Sanofi Investment of Up to $60 Million | Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on diseases of the eye, today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44... |
| 08.11.2021 | Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million | - |
| 08.11.2021 | Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million | LONDON – 8 November 2021 – Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on diseases of the eye, today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to... |
| 30.09.2021 | Gyroscope announces presentation of positive interim Phase I/II data for investigational gene therapy GT005 | Gyroscope Therapeutics announces presentation of positive interim Phase I/II data for investigational gene therapy GT005 at Retina Society Annual Scientific Meeting
GT005 Continues to be Well Tolerated with Encouraging Biomarker Results in ... |
| 22.06.2021 | Gyroscope Therapeutics announces research collaboration agreement with Children’s Medical Research Institute | Gyroscope Therapeutics announces research collaboration agreement with Children’s Medical Research Institute to develop novel gene therapy capsids
Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focu... |
| 29.03.2021 | CIC participates in Gyroscope Therapeutics’ £107.8 million Series C financing | CIC participates in Gyroscope Therapeutics’ £107.8 million Series C financing
29-03-2021
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life science businesses in the Cambridge ecosystem, is pleased... |
| 26.03.2021 | Gyroscope Therapeutics Raises $148M in Series C Financing | Gyroscope Therapeutics Limited, a London, UK-based clinical-stage gene therapy company focused on treating diseases of the eye, raised USD $148.0m in Series C financing.
The round was led by Forbion’s Growth Opportunities Fund and includes ... |
| 26.03.2021 | Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing | Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye, announced today it has raised USD $148.0 million (£107.8 million) in a Series C financing. The financing was led by Forbion’s Gro... |
| 26.03.2021 | Forbion’s Growth Opportunities Fund leads $148M Series C Financing for Gyroscope Therapeutics | Amsterdam, The Netherlands, 26 March 2021 – Forbion, a leading European life sciences venture capital firm, today announces that its Growth Opportunities Fund has led a USD $148 million (GBP £107.8M million) Series C financing for Gyroscope... |
| 26.03.2021 | CIC participates in Gyroscope Therapeutics’ £107.8 million ($148 million) Series C financing | Cambridge Innovation Capital participates in Gyroscope Therapeutics’ £107.8 million ($148 million) Series C financing
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life science businesses in the Ca... |
| 26.03.2021 | Gyroscope bags $148M for AMD gene therapy trials, mulls IPO
Remarque Systems: Content Hub | Gyroscope Therapeutics has raised $148 million to advance a pipeline of ocular gene therapies. The series C, which could be a precursor to an IPO, positions Gyroscope to build on recent early-phase data on lead candidate GT005.
Gyroscope is... |
| 26.03.2021 | Syncona cornerstones $148m Series C in Gyroscope | Syncona cornerstones $148m Series C in Gyroscope
Business Weekly article | By Tony Quested
Eye disease technology from Gyroscope in Stevenage is set to become increasingly influential globally following a $148 million Series C raise.
Health... |
| 26.03.2021 | T. Rowe Price Joins $148 Million Series C for Gyroscope Therapeutics | LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye, announced today it has raised USD $148.0 million (£107.8 million) in a Series C financing. The financing... |
| 26.03.2021 | Gyroscope bags $148M for AMD gene therapy trials, mulls IPO | Gyroscope Therapeutics has raised $148 million to advance a pipeline of ocular gene therapies. The series C, which could be a precursor to an IPO, positions Gyroscope to build on recent early-phase data on lead candidate GT005.
London-based... |
| 01.03.2021 | Gyroscope Therapeutics appoints Jessica Stitt as Chief Financial Officer | Gyroscope Therapeutics appoints Jessica Stitt as Chief Financial Officer
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the appointment of Jessica Stitt as Chief Financi... |
| 01.03.2021 | Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer | LONDON--(BUSINESS WIRE)--Mar 1, 2021--
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the appointment of Jessica Stitt as Chief Financial Officer, effective immediately.... |
| 27.01.2021 | A year in review: Business update January 2021 | Cambridge has always been at the forefront of innovation. As the leading venture capital investor in Cambridge, CIC plays a central role in commercialising this innovation for the benefit of society. In the last year, CIC’s existing portfol... |
| 18.12.2020 | Gyroscope Therapeutics and the University of Pennsylvania announce research agreement | Gyroscope Therapeutics and the University of Pennsylvania announce research agreement to develop gene therapies for serious eye diseases
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, t... |
| 02.12.2020 | Gyroscope announces appointments of industry veterans to the Board of directors | Gyroscope Therapeutics announces appointments of industry veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to its Board of Directors
Gyroscope Therapeutics, a clinical-stage retinal gene therapy company, today announced that J... |
| 11.11.2020 | Gyroscope announces first patient dosed in Phase II HORIZON Trial | Gyroscope Therapeutics announces first patient dosed in Phase II HORIZON Trial evaluating investigational gene therapy, GT005, in people with dry age-related macular degeneration
U.S. FDA grants second fast track designation to GT005 for Tr... |
| 28.10.2020 | Gyroscope announces first patient has received investigational gene therapy | Gyroscope Therapeutics announces first patient received investigational gene therapy GT005 via orbit subretinal delivery system in ongoing Phase I/II FOCUS trial
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company,... |
| 22.09.2020 | Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005 | Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced tha... |
| 11.09.2020 | Gyroscope announces appointment of Sean Bohen to the Board of directors | Gyroscope Therapeutics announces appointment of Sean Bohen to the Board of directors
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that biotech industry veteran Sean Bohen, M.D., Ph.D., has b... |
| 03.09.2020 | Gyroscope Therapeutics secures £50.4 million in Series B financing | Gyroscope Therapeutics secures £50.4 million in Series B financing to continue clinical development of gene therapies and surgical delivery systems for retinal diseases
Gyroscope Therapeutics Limited, a company developing gene therapies and... |
| 25.08.2020 | Gyroscope Therapeutics announces FDA clearance for orbit subretinal delivery system | Gyroscope Therapeutics announces FDA clearance for orbit subretinal delivery system
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food & Drug Administration (FDA) has grante... |
| 13.08.2020 | Gene therapy for dry age-related macular degeneration | Gyroscope Therapeutics, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dr... |
| 03.09.2019 | CIC participates in Gyroscope Therapeutics’s £50.4 million Series B funding | Financing will support continued clinical development of gene therapies and surgical delivery systems for retinal diseases
Cambridge Innovation Capital plc (CIC), the venture capital investor enabling visionaries to build global, category-l... |
| 11.04.2019 | Gyroscope Therapeutics merges with Orbit Biomedical | Gyroscope Therapeutics merges with Orbit Biomedical creating a leading retinal gene therapy company
Merger brings together sub-retinal surgical delivery technology with Gyroscope’s clinical stage pipeline and gene therapy manufacturing plat... |
